NMC Health – founder and two associates walk the plank with immediate effect in wake of shares scandal
When I first commented on AIM-listed cancer drug developer ValiRx (VAL) back in 2016 the shares had just seen a pump’n’dump which pushed the stock up to 21p before a placing at just 12p. Now the stock is just 0.1p and on a market cap of £0.9m (source: ADVFN): never mind the 90% club, this is a fully paid up member of the 99% club. And now we have a placing for just £200,000 gross…..and Broker number three joins the fray, although as Tom Winnifrith points out the RNS will have to be reissued. How on earth can you justify paying three broker retainers for a company worth less than a million pounds?
I do not wish to be seen as a pedant but an RNS statement is meant to be, you know, like, er, accurate. And thus as an upstanding member of the AIM Casino community I have penned a quick email to my pal Liam Murray at Nomad Cairn Financial about today's RNS from ValirX (VAL) which appears to fail the accuracy test. I write.
Perhaps ValiRx (VAL) should be making a statement about events at Valiseek?
In this video from the storming success that was the 2017 UK Investor Show, Satu Vainikka of Valirx (VAL) is at the podium. And make sure that you keep April 21 2018 free for next year's UK Investor Show.
I was delighted to read this morning’s RNS from AIM-listed cancer-buster ValiRx (VAL): it has ditched the value-destroying funding package with Bracknor. About time too, this has been a disaster for the share price ever since it was announced back in March. With the shares having crashed from 12.5p the day before the package was announced to the current 6.875p (last seen) the damage has been horrific.
AIM-listed cancer-buster ValiRx (VAL) has its EGM today at 11.30am at the offices of DAC Beachcroft LLP, 100 Fetter Lane, London EC4AS 1BN. After shareholders voted to reject a resolution to disapply pre-emption rights at the AGM a couple of weeks back, the company has called a new gathering at which shareholders are being asked to vote on it again with management hoping that this time the shareholders get the answer right. Heck, it works for the EU, so why not here? Update - motion passed, shares down.
I highlighted yesterday that it seemed to me that the failure of shareholders in AIM-listed cancer-buster ValiRx to pass a special resolution at last week’s AGM to disapply pre-emption rights cast a bit of a shadow over the company’s funding arrangements. In a move straight out of the EU rulebook on democracy, shareholders are to be given the (ahem) opportunity to vote again in the hope of coming up with the right answer this time.
Shareholders in AIM-listed cancer-buster ValiRx (VAL) rejected a disapplication of pre-emption rights special resolution at the AGM held last Monday. The company said a further announcement would follow “in due course” but since then there has been silence. But it seems that there might be a few implications for the financing of the company going forward.
This morning saw AIM-listed ValiRx (VAL) appoint Beaufort Securities as Joint Broker. This coincided with a quarterly update RNS full of good news and Beaufort included a generous write-up in today’s morning note, with a “speculative buy” rating. All jolly good, but I fear that yet more errors have been made by the company.
After-hours (natch) yesterday AIM-listed biotech ValiRx (VAL) released an RNS announcing the drawdown of the second £500,000 tranche (of up to eight) of its convertible death spiral funding package with Bracknor. We were also told that half of it had already been converted, with reference made to the terms set out in an RNS of 21 March 2016. But the numbers simply don’t add up – oh, and the company had now admitted that associated warrants will have to be approved by shareholders.
And now for a video from the biotech boss who I have sworn to be nice to, Dr Satu Vainikka of ValiRx (VAL) presenting at UK Investor Show. Enjoy.
AIM-listed ValiRx (VAL) operates in the biotech space, developing cancer drugs. I’ve been pretty beastly in previous pieces (see HERE) but I am pleased to note that the company has seen fit to address the questions asked over Companies House filings. As pointed out HERE they were indeed wrong and they have now been corrected. Good news. My hope is that the questions over the Bracknor funding deal will now be addressed.
After-hours last night (5pm) AIM-listed ValirX (VAL) announced a second batch of loan conversions under its £4 million (except it is up to £8.6 million) funding deal with Bracknor. It was at just 7.4p so it is no great surprise that the shares are down at 8.625p mid (last seen) having closed last night at 9.25p. But then there are those warrants….does anyone have the slightest Scooby of what’s going on there from last night’s announcement?
Yesterday I had a few comments to offer with regard to AIM-listed ValiRx (VAL) and its £4 million (or is it £8.6 million, or is it £8.6 million plus proceeds from exercise of 5 million warrants at 9p?) CUL deal with Bracknor. My fear is that details of that deal offered up in the RNS of 21 March 2015 look (from Friday’s RNS) to have been incredibly lacking. But wandering over to the Companies House website leaves me wondering if the company can’t get simple Companies House filings right, what hope is there for the mechanics of a complex CUL deal to be fully understood and conveyed to shareholders?
On 21 March this year, AIM-listed ValiRx (VAL) announced a convertible loan facility with Bracknor Fund Ltd. It was announced that the company could draw down up to £4 million in tranches of £500,000. But it seems that some of the information given was either wrong or just missing, not to mention a small problem of share issuance authorities which look to be insufficient to seal the deal. Having had no reply to two emails sent to the company, I am assuming that the conclusions I have come to are correct. It is not pretty.
Two positive-looking RNSs, one each on 9 Feb and 16 Feb saw shares in AIM-listed ValiRx (VAL) shifting about sharply. On 9 Feb the shares shot up from a previous close of 15p and peaking at 18.25p before topping out at 21p the following day. Then Tuesday's news saw the shares close down at 13.25. And lo and behold yesterday we had a keep-the-lights on placing to raise £0.5 million at just 12p a share.
Featuring China New Energy, Coms, Legendary Investments, Tern, Valirx
Forget all the jam tomorrow garbage from serial cash burning biotech loser ValiRX (VAL) the half year report out this morning is a dog’s dinner. Look at the numbers.
If you want me to analyse a stock for you just drop me a line at email@example.com - Today I look at shares in Feedback (FDBK), MySale (MYSL) and Valirx (VAL) setting a share price target for each.
On December 5, I was lambasted by Bulletin Board Morons for being beastly to ValiRX (VAL) – the 0.285p in the middle (down by 98% under current management). Apparently I did not understand the science.
You see my problem is that I just do not understand the exciting technology. That is what the ValiRx (VAL) experts say, well by experts I mean Bulletin Board Morons. We have been here before. Do you remember Monitise?
In today’s BearCast I suggested that ValiRX (VAL) might be suspended as its Nomad was Daniel Stewart and it needed a new Nomad and that no Nomad with any degree of integrity would take on this utter POS company. I apologise for one error in that assertion.
As far as shares of Valirx (VAL) goes, I would guess there are a few in the market who would award the company any brownie points in the wake of the latest placing (largely via a death spiral) tucked in beautifully between Christmas and New Year.
Search ShareProphets |
Recent Comments |